A Phase 4 Trial Assessing the ImPact of Residual Inflammation Detected Via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical Remission Rheumatoid ArThritis (RA) Subjects
Public ClinicalTrials.gov record NCT02198651. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 4 Trial Assessing the ImPact of Residual Inflammation Detected Via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical Remission Rheumatoid ArThritis (RA) Subjects (PREDICTRA)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of the study was to investigate the association between residual disease activity at Baseline as detected by Magnetic Resonance Imaging (MRI) and the occurrence of flares in participants with rheumatoid arthritis (RA) randomized to an adalimumab dose tapering regimen controlled by adalimumab withdrawal.
Study identification
- NCT ID
- NCT02198651
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 149 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 5, 2015 (Actual)
- Primary completion
- May 3, 2018 (Actual)
- Completion
- Aug 8, 2018 (Actual)
- Last update posted
- Jun 25, 2019
2015 – 2018
United States locations
- U.S. sites
- 13
- U.S. states
- 13
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| J Michael Grelier Research /ID# 149772 | Tuscaloosa | Alabama | 35406 | — |
| Westlake Medical Research (WMR) Clinical Trials /ID# 155386 | Thousand Oaks | California | 91360-3994 | — |
| University of Florida /ID# 144851 | Jacksonville | Florida | 32209 | — |
| North Georgia Rheumatology Grp /ID# 155225 | Lawrenceville | Georgia | 30045 | — |
| The Arthritis & Diabetes Clinic, Inc. /ID# 149017 | Monroe | Louisiana | 71203 | — |
| Aa Mrc Llc /Id# 151933 | Grand Blanc | Michigan | 48439 | — |
| North Mississippi Med Clinics /ID# 149443 | Tupelo | Mississippi | 38801 | — |
| Montefiore Medical Center /ID# 155013 | The Bronx | New York | 10461 | — |
| Shanahan Rheuma & Immuno /ID# 148689 | Raleigh | North Carolina | 27617 | — |
| Altoona Ctr Clinical Res /ID# 148448 | Duncansville | Pennsylvania | 16635 | — |
| Low Country Rheumatology, PA /ID# 154198 | Summerville | South Carolina | 29486 | — |
| West Tennessee Research Inst /ID# 148391 | Jackson | Tennessee | 38305 | — |
| Arthritis Centers of Texas /ID# 152843 | Dallas | Texas | 75246 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 57 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02198651, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 25, 2019 · Synced Oct 30, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02198651 live on ClinicalTrials.gov.